Anest. intenziv. Med. 2005;16(4):203-209

PIRO concept - "P" (predisposition) and sepsisIntensive Care Medicine - Original Paper

M. Průcha, V. Ma»oąka
Oddělení klinické biochemie, hematologie a imunologie, Nemocnice Na Homolce, Praha

The letter "P" means "predisposition" in the PIRO concept for the staging of sepsis. Different methods of molecular biology enable us to determine the genetic predisposition in both monogenic and polygenic diseases. Sepsis represents an example of a polygenic disease. The determination of genetic polymorphism of inflammatory mediators, parameters of innate immunity and haemocoagulation factors represent just one approach. The DNA microarray technology holds a promise to monitor the interaction of thousands of genes simultaneously and represents the diagnostic tool of the future. It will be necessary to coordinate clinical trials in order to make good use of these diagnostic methods.

Keywords: DNA microarray; genetic polymorfism; PIRO concept; predisposition; sepsis

Published: August 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Průcha M, Ma»oąka V. PIRO concept - "P" (predisposition) and sepsis. Anest. intenziv. Med. 2005;16(4):203-209.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. International SNP MAP Working Group: A map of human genome sequence variation containing 1,4 million single nucleotide polymorphisms. Nature, 2001, 409, p. 928-933. Go to original source... Go to PubMed...
    2. Chung, T. P., Laramie, J. M., Province, M. et al. Functional genomics of critical illness and injury. Crit. Care Med., 2002, 30, Suppl, S51-S57. Go to original source...
    3. Sorensen, T. I., Nielsen, G. G., Anderson, P. K., Teasdale, T. W. Genetic and environmental influences on premature death in adult adoptees. N. Engl. J. Med., 1988, 318, p. 727-732. Go to original source... Go to PubMed...
    4. Cooke, G. S., Hill, A. V. S. Genetics of susceptibility to human infectious disease. Nat. Rev. Gen., 2001, 2, p. 967-977. Go to original source... Go to PubMed...
    5. Bone, R. C., Balk, R. A., Cerra, F. B. et al. ACCP/SCCM consensus conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest, 1992, 101, p. 1644-1655. Go to original source... Go to PubMed...
    6. Enghild, J. J., Thogersen, I. B., Salvesen, M. et al. α-macroglobulin from Limulus polyphemus exhibits proteinase activity and participates in a hemolytic system. Biochemistry, 1990, 29, p. 10070-10080. Go to original source... Go to PubMed...
    7. Triantafilou, M., Triantafilou, K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol., 2002, 23, p. 301-304. Go to original source... Go to PubMed...
    8. Tobias, P. S., Soldau, K., Iovine, N. M. et al. Lipopolysaccharide (LPS)-binding proteins BPI and LBP from different types of complexes with LPS. J. Biol. Chem., 1997, 272, p. 18682-18685. Go to original source... Go to PubMed...
    9. Landmann, R., Zimmerli, W., Sansano, S. et al. Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J. Infect. Dis., 1995, 171, p. 639-644. Go to original source... Go to PubMed...
    10. Burgmann, H., Winkler, S., Locker, G. J. et al. Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Clin. Immunol. Immunopathol., 1996, 80, p. 307-310. Go to original source... Go to PubMed...
    11. Hubacek, J. A., Stuber, F., Frohlich, D. et al. C (-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes. Immun., 2000, 1, p. 405-407. Go to original source... Go to PubMed...
    12. Gibot, S., Cariou, A., Drouet, L. et al. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit. Care Med., 2002, 30, p. 969-973. Go to original source... Go to PubMed...
    13. Hubacek, J. A., Stuber, F., Frohlich, D. et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: Gender-specific predisposition to sepsis. Crit. Care Med., 2001, 29, p. 557-561. Go to original source... Go to PubMed...
    14. Beutler, B. Toll-like receptors: How they work and what they do. Curr. Opin. Hematol., 2002, 9, p. 2-10. Go to original source... Go to PubMed...
    15. Poltorak, A., He, X., Smirnova, I. et al. Defective LPS signaling in CH3/HeJ and C57BL/10ScCr mice: Mutations in Tir4 gene. Science, 1998, 282, p. 2085-2088. Go to original source... Go to PubMed...
    16. Arbour, N. C., Lorenz, E., Schutte, B. C. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet., 2000, 25, p. 187-191. Go to original source... Go to PubMed...
    17. Lorenz, E., Mira, J. P., Frees, K. L. et al. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch. Intern. Med., 2002, 162, p. 1028-1032. Go to original source... Go to PubMed...
    18. Read, R. C., Pullin, J., Gregory, S. et al. A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J. Infect. Dis., 2001,184, p. 640-642. Go to original source... Go to PubMed...
    19. Smirnova, I., Mann, N., Dois, A. et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc. Natl. Acad. Sci. USA, 2003, 100, p. 6075-6080. Go to original source... Go to PubMed...
    20. Brightbill, H. D., Libraty, D. H., Krutzik, S. R. et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science, 1999, 285, p. 732-736. Go to original source... Go to PubMed...
    21. Lorenz, E., Mira, J. P., Cornish, J. L. et al. A novel polymorphism in the toll-like receptor gene and its potential association with staphylococcal infection. Infect. Immun., 2000, 68, p. 6398-6401. Go to original source... Go to PubMed...
    22. Dinarello, C. A. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest, 1997, 112, 6 Suppl, p. 321S-329S. Go to original source... Go to PubMed...
    23. Nakane, A., Minagawa, T., Kato, K. et al. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogene infection. Infect. Immun., 1988, 56, p. 2563-2569. Go to original source... Go to PubMed...
    24. Abraham, E., Wunderink, R., Silverman, H. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. JAMA, 1995, 273, p. 934-941. Go to original source... Go to PubMed...
    25. Wilson, A. G., Symons, J. A., McDowell, T. L. et al. Effects of a polymorphism in the human tumor necrosis factor alpha-promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA, 1997, 94, p. 3195-3199. Go to original source... Go to PubMed...
    26. Stuber, F., Udalova, I. A., Book, M. et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J. Inflamm., 1996, 46, p. 42-50.
    27. Tang, G. J., Huang, S. L., Yien, H. W. et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit. Care Med., 2000, 28, p. 2733-2736. Go to original source... Go to PubMed...
    28. Mira, J. P., Cariou, A., Grall, F. et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA, 1999, 282, p. 561-568. Go to original source... Go to PubMed...
    29. Waterer, G. W., Quasney, M. W., Cantor, R. M. et al. Septic shock and respiratory failure in community-aquired pneumonia have different TNF polymorphism associations. Am. J. Respir. Crit. Care Med., 2001, 163, p. 1599-1564. Go to original source... Go to PubMed...
    30. Stuber, F., Petersen, M., Bokelman, F. et al. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit. Care Med., 1996, 24, p. 381-384. Go to original source... Go to PubMed...
    31. Majetschak, M., Flohe, S., Obertacke, U. et al. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann. Surg., 1999, 230, p. 207-214. Go to original source... Go to PubMed...
    32. Pociot, F., Molvig, J., Wogensen, L. et al. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest., 1992, 22, p. 396-402. Go to original source... Go to PubMed...
    33. di Giovine, F. S., Takhsh, E., Blakemore, A. L. et al. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum. Mol. Genet., 1992, 1, p. 450. Go to original source... Go to PubMed...
    34. Tarlow, J. K., Blakemore, A. I., Lennard, A. et al. Polymorhism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum. Genet., 1993, 91, p. 403-404. Go to original source... Go to PubMed...
    35. Hu r me, M., Santtila, S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and Il-1beta genes. Eur. J. Immunol., 1998, 28, p. 2598 till 2602. Go to original source... Go to PubMed...
    36. Fan, X. M., Schorder, S., Hoeft, A. et al. Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit. Care Med., 1999, 27, p. 1330-1334. Go to original source... Go to PubMed...
    37. Ma, P., Chen, D., Pan, J. et al. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit. Care Med., 2002, 30, p. 1046-1050. Go to original source... Go to PubMed...
    38. Ar nalich, F., Lopez-Maderuelo, D., Codeceo, R. et al. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin. Exp. Immunol., 2002, 127, p. 331-335. Go to original source... Go to PubMed...
    39. Penglin, M., Dechang, Ch., Jiaqi, P. et al. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit. Care Med., 2002, 30, p. 1046-1050. Go to original source... Go to PubMed...
    40. Van der Poll, T., Van Deventer, J. H. Interleukin-6 in bacterial infection and sepsis: innocent bystander or essential mediator? In Vincent, J.L. (eds) Yearbook of Intensive Care and Emergency Medicine, Springer 1999, p. 43-54. Go to original source...
    41. Tilg, H., Trehu, E., Atkins, M. B. et al. Interleukin-6(IL-6) as an antiinflammatory cytokine"induciton of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood, 1994, 83, p. 113-118. Go to original source...
    42. Van der Poll, T., Keogh, C. V., Buurman,W. A., Lowry, S. F. Passive immunization against tumor necrosis factor impairs host defense during pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med., 1997, 155, p. 603-608. Go to original source... Go to PubMed...
    43. Reinhart, K., Menges, T., Gradlund, B. et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit. Care Med., 2001, 29, p. 765-769. Go to original source... Go to PubMed...
    44. Schluter, B., Raufhake, C., Erren, M. et al. Effect of the interleukin-6 promoter polymorphism (-174G/C) on the incidence and outcome of sepsis. Crit. Care Med., 2002, 30, p. 32-37. Go to original source... Go to PubMed...
    45. Heesen, M., Obertacke, U., Schade, F. U. et al. The interleukin-6 G (-174)C polymorphism and the ex vivo interleukin-6 response to endotoxin in severely injured blunt trauma patiens. Eur. Cytokine Netw., 2002, 13, p. 72-77. Go to PubMed...
    46. Boehm, U., Klamp, T., Groot, M. et al. Cellular response to interferon-gamma. Annu. Rev. Immunol., 1997, 15, p. 749-795. Go to original source... Go to PubMed...
    47. Pollack, M. Blood exchange and plasmapheresis in sepsis and septic shock. Clin. Infect. Dis., 1992, 15, p. 424-430. Go to original source... Go to PubMed...
    48. Nierhaus, A., Montag, B., Timmler, N. et al. Reversal of immunoparalysis by recombinant human granulocyte - macrophage colony stimulating factor in patients with severe sepsis. Inten. Care Med., 2003 (on-line, Springer-Verlag 2003, 10.1007/s00134-003-1666-6). Go to original source...
    49. Stassen, N. A., Leslie-Norfleet, L. A., Robertson, A. M. et al. Interferon-gamma gene polymorphisms and the development of sepsis in patiens with trauma. Surgery, 2002, 132, p. 289-292. Go to original source... Go to PubMed...
    50. Davis, E. G., Eichenberger, M. R., Grant, B. S. et al. Microsatellite marker of interferon-gamma receptor 1 gene correlates with infection following major trauma. Surgery, 2000, 128, p. 301-305. Go to original source... Go to PubMed...
    51. Levi, M., Keller, T. T., van Gorp, E., Cate, H. Infection an inflammation and the coagulation system. Cardiovasc. Res., 2003, 60, p. 26-39. Go to original source... Go to PubMed...
    52. Gando, S., Nanzaki, S., Morimoto, Y. et al. Systemic activation of tissue-factor dependent coagulation pathway in evolving acute respiratory distress syndrome in patients with trauma and sepsis. J. Trauma, 1999, 47, p. 719-723. Go to original source... Go to PubMed...
    53. Aird, W. C. Vascular bed-specific hemostasis: Role of endothelium in sepsis pathogenesis. Crit. Care Med., 2001, 29, 7, Suppl, p. S28-S35. Go to original source... Go to PubMed...
    54. Faust, S. N., Levin, M., Harison, O. B. et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med., 2001, 345, p. 408-416. Go to original source... Go to PubMed...
    55. Paramo, J. A., Perez, J. L., Serrano, M. et al. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb. Haemost., 1990, 64, p. 30-36. Go to original source...
    56. Brandyaeg, P., Joo, G. B., Brusleto, B. et al. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb. Res., 1990, 57, p. 271-278. Go to original source... Go to PubMed...
    57. Eriksson, P., Kallin, B., van Hooft, F. M., et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA, 1995, 92, p. 1851-1855. Go to original source... Go to PubMed...
    58. He r mans, P. W., Hibberd, M. L., Booy, R. et al. 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet, 1999, 354, p. 555-560. Go to original source... Go to PubMed...
    59. Westendorp, R. G., Hottenga, J. J., Slagboom, P. E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet, 1999, 354, p. 561-563. Go to original source... Go to PubMed...
    60. Haralambous, E., Hibberd, M. L., He r mans, P. W. M. et al. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit. Care Med., 2003, 31, p. 2788-2793. Go to original source... Go to PubMed...
    61. Menges, T., H e r mans, P. W., Little, S. G. et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet, 2001, 357, p. 1096-1097. Go to original source... Go to PubMed...
    62. Jenner, R. G., Young, R. A. Insights into host responses against pathogens from transcriptional profiling. Nature Rev. Microbiology, 2005, 3, p. 281-294. Go to original source... Go to PubMed...
    63. Pr ucha, M., Ruryk, A., Hinnerk, B. et al. Expression Profiling: Toward an application in sepsis diagnostics. Shock, 2004, 22, p. 29-34. Go to original source... Go to PubMed...
    64. van Veer, L. J., Dai, H., van de Vijver, M. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415, p. 530-536. Go to original source... Go to PubMed...
    65. Mutlu, G. M., Ahkmedov, A. T., Lu, H. et al. Potential genetic therapies for acute lung injury. Current Gene. Therapy, 2004, 4, p. 487-495. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.